socaltech.com
Los Angeles-based
Appia Bio, a biotech startup focused on developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, has launched from stealth mode, saying it has raised $52M in a Series A funding round. The funding was led by 8VC, and also included Two Sigma Ventures, Sherpa Healthcare Partners and Freeflow Ventures. The company said its technology was originally developed in the laboratory of Lili Yang, PhD, associate professor at University of California, Los Angeles (UCLA). Appia said that Francisco Gimenez, PhD, and David Moskowitz, PhD, of 8VC, both join the company s board, with David Baltimore, PhD, of the California Institute of Technology (Caltech) serving as Chairman. The company said the proceeds from the funding will go to support advancement of its therapy candidates.
Alebund Pharmaceuticals, a Shangai, China-based biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, raised $60m in Series B financing.
The round was led by Quan Capital, with participation from 3E Bioventures Capital, and Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Med-Fine Capital.
The company intends to use the funds for research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion its talent pool.
Founded in Shanghai in early 2018 as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures, Alebund is a clinical stage biopharmaceutical company dedicated to the discovery and development of novel therapies and providing clinical solutions to patients with kidney diseases and related chronic conditions.
Photo: Pixabay
April 22, 2021
Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation.
The Series B+ round roped in new investors BioTrack Capital and Sherpa Healthcare Partners, two China-focused, healthcare venture capital (VC) companies. The firm’s existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and Kunlun Capital re-upped in the deal.
Founded in 2015, EdiGene is a clinical-stage biotech company that focuses on leveraging genome editing technologies to accelerate drug discovery and to develop novel therapeutics for a broad range of genetic diseases and cancer. The startup has established its proprietary
Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc
April 1, 2021
Immune-Onc Therapeutics, a California-based cancer immunotherapy firm co-founded by Chinese pharma specialist Charlene Liao, has raised $73 million in Series B1 and B2 rounds of financing, it announced earlier this week.
The latest funding brings the total capital raised by the company to $110 million, it said in a statement.
Beijing-headquartered Oceanpine Capital was the lead investor in the two rounds, which were joined by return backers Northern Light Venture Capital and Vivo Capital. Following the financing, Oceanpine CEO and managing partner Dave Chenn joined the Immune-Onc board of directors.
The biopharma firm’s Series B1 and B2 rounds also attracted a slew of Chinese investors, including South China Venture Capital, Sherpa Healthcare Partners, BOCOM International Holdings, Triwise Capital, Qianzhan Investment, Yanchuang Capital, Tao Capital and Yinglian Healthcare Fund.
VISEN s TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.